Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MedPlus Health Services Ltd. ( (IN:MEDPLUS) ) has provided an update.
MedPlus Health Services Limited has disclosed that its subsidiary, Optival Health Solutions Private Limited, received a three-day suspension of the drug license for one retail pharmacy in Kalyan Nagar, Dharwad, Karnataka. The order was issued by the Assistant Director of the Drugs Control Administration, Hubli Circle, under Rule 65 of the Drugs and Cosmetics Act, 1940 and the accompanying Rules, and was received on March 27, 2026.
The company estimates a potential revenue loss of Rs 0.66 lakh from this short-term suspension, suggesting a limited financial impact on overall operations. However, the regulatory action underscores ongoing compliance scrutiny in the pharmaceutical retail sector, signaling to stakeholders the importance of strict adherence to drug licensing norms at the store level.
More about MedPlus Health Services Ltd.
MedPlus Health Services Limited operates in the healthcare and pharmaceutical retail industry in India, primarily through its pharmacy chain and related health services. The company serves consumers across multiple states, offering prescription medicines, over-the-counter drugs, and health products via its own stores and subsidiaries such as Optival Health Solutions Private Limited.
Average Trading Volume: 18,206
Technical Sentiment Signal: Buy
Current Market Cap: 99.31B INR
For detailed information about MEDPLUS stock, go to TipRanks’ Stock Analysis page.